New eye drop shows promise for allergy itch
NCT ID NCT04622345
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial tested whether VSJ-110 eye drops can reduce itching and redness caused by allergic conjunctivitis (eye allergies). 47 adults received either the active eye drop or a placebo, then were exposed to an allergen. The study measured how much their eyes itched and reddened in the minutes after exposure. Results will show if VSJ-110 works better than placebo for quick symptom relief.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- VSJ-110 ophthalmic solution (eye drops)
- What this could lead to
- If it works, this could lead to a new eye drop that quickly relieves itching and redness caused by eye allergies.
- What could go wrong
- This is a small, early-phase trial (47 people) testing a short-term response in a lab setting. Real-world effectiveness and long-term safety are unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALLERGIC CONJUNCTIVITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Vanda Investigational Site
Andover, Massachusetts, 01810, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Experimental antibodies aim to block cat allergy eye itch
- Eye insert could ease allergy symptoms for contact lens wearers
- New eye drops zap allergy itch in just minutes
- Which eye drop stings less? small study pits flarex against lotemax SM
- Scientists hunt for eye disease clues in your tears
- Can ectoin sprays and drops soothe hay fever? new study investigates